ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis.

Bütikofer, Lukas; Varisco, Pierre A; Distler, O; Kowal-Bielecka, O; Allanore, Y; Riemekasten, G; Villiger, P.M.; Adler, S. (2020). ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. Arthritis research & therapy, 22(1), p. 59. BioMed Central 10.1186/s13075-020-2141-2

[img]
Preview
Text
Bütikofer ArthritisResTher 2020 .pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

OBJECTIVES

To investigate the effect of ACE inhibitors (ACEi) on the incidence of scleroderma renal crisis (SRC) when given prior to SRC in the prospectively collected cohort from the European Scleroderma Trial and Research Group (EUSTAR).

METHODS

SSc patients without prior SRC and at least one follow-up visit were included and analyzed regarding SRC, arterial hypertension, and medication focusing on antihypertensive medication and glucocorticoids (GC).

RESULTS

Out of 14,524 patients in the database, we identified 7648 patients with at least one follow-up. In 27,450 person-years (py), 102 patients developed SRC representing an incidence of 3.72 (3.06-4.51) per 1000 py. In a multivariable time-to-event analysis adjusted for age, sex, disease severity, and onset, 88 of 6521 patients developed SRC. The use of ACEi displayed an increased risk for the development of SRC with a hazard ratio (HR) of 2.55 (95% confidence interval (CI) 1.65-3.95). Adjusting for arterial hypertension resulted in a HR of 2.04 (95%CI 1.29-3.24). There was no evidence for an interaction of ACEi and arterial hypertension (HR 0.83, 95%CI 0.32-2.13, p = 0.69). Calcium channel blockers (CCB), angiotensin receptor blockers (ARB), endothelin receptor antagonists, and GC-mostly in daily dosages below 15 mg of prednisolone-did not influence the hazard for SRC.

CONCLUSIONS

ACEi in SSc patients with concomitant arterial hypertension display an independent risk factor for the development of SRC but are still first choice in SRC treatment. ARBs might be a safe alternative, yet the overall safety of alternative antihypertensive drugs in SSc patients needs to be further studied.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology
04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern

UniBE Contributor:

Bütikofer, Lukas; Villiger, Peter and Adler, Sabine

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

1478-6354

Publisher:

BioMed Central

Language:

English

Submitter:

Andrea Flükiger-Flückiger

Date Deposited:

31 Mar 2020 10:51

Last Modified:

25 Sep 2020 09:56

Publisher DOI:

10.1186/s13075-020-2141-2

PubMed ID:

32209135

Uncontrolled Keywords:

ACE inhibitors Antihypertensive drugs Arterial hypertension Outcome Scleroderma renal crisis

BORIS DOI:

10.7892/boris.142735

URI:

https://boris.unibe.ch/id/eprint/142735

Actions (login required)

Edit item Edit item
Provide Feedback